

In vitro dissolution study of Glimepiride from binary and ternary Solid dispersion Formulation

Abstract:

Glimepiride (GMP) is poorly water soluble drug, so solubility is the main constraint for its oral bioavailability. Because, poor aqueous solubility and slow dissolution rate of the glimepiride lead to irreproducible clinical response or therapeutic failure in some cases due to sub therapeutic plasma drug levels. In this study, binary and ternary solid dispersion of glimepiride were prepared with poloxamer 407, polyethylene glycol 6000 (PEG 6000), polyethylene glycol 4000 (PEG 4000), and eudragit at different weight ratios using the solvent evaporation and melting method. Fusion method of the poloxamer 407 and Eudragit with glimepiride at different ratios were also used. It was found the drug was released 0.46% after 5 minutes and only 15.83% within 60 minutes from active glimepiride on the other hand the release pattern of glimepiride from the binary formulation containing PEG 4000 in 1:5 (Formulation coding: G5) showed the best result. It was found that the ternary different SD formulation containing (PEG4000:Glimepiride:Povidon) In ratio 1:1:0.25 (Formulation coding were : G13) showed the best result. It was also studied that the release kinetics of glimepiride of different SD formulation with different ratio such as, First order release kinetics, Higuchi, Krosmeier, Hixoncrowell plot, and also be noted the MDT calculation for improving the solubility of glimepiride. Formulations were characterized by Fourier transform infrared (FTIR) and X-ray diffraction (XRD). No any chemical interaction was observed between polymer and drugs from IR spectrum. The drug was changed to amorphous form after solid dispersion. It was also evident that solid dispersions improve solubility of drug particles thus enhancing dissolution characteristics of drugs they increase the oral bioavailability.

Key words: Glimepiride, Fusion Method, Dissolution Study, Formulation, IR spectrum.

*Corresponding Author: Md. Shahidul Islam, Assistant Professor, Department of Pharmacy, University of Science & Technology Chittagong, Bangladesh. E-mail: s_i_liton@yahoo.com

Introduction

It has studied that, improving oral bioavailability of drugs those given as solid dosage forms remains a challenge for the formulation scientists due to solubility problems. Most of the newly invented chemical entities are poorly water soluble. As a result formulating them as oral solid dosage forms is a hurdle to the specialists. Many techniques have been exercised to improve oral bioavailability of drugs (1). The rate of dissolution and solubility should not be confused as they are different concepts, kinetic and thermodynamic, respectively. The solubilization kinetics, as

well as apparent solubility can be improved after complexation of an active ingredient with cyclodextrin. This can be used in the case of drug with poor solubility(2).The oral route of administration is the most preferred and widely acceptable route of delivery due to ease of ingestion for many drugs. Drugs with slow dissolution rate show the incomplete absorption leading to low bioavailability when orally administered (3). Many of the drugs belong to class II of the biopharmaceutical classification system showing poor solubility and high permeability. Glimepiride shows low, pH dependent solubility. In acidic and neutral aqueous media, glimepiride exhibits very poor solubility at 37°C (<0.004 mg/ml). In media pH>7, solubility of drug is slightly increased to 0.02 mg/ml. These poorly water soluble drugs provide challenges to deliver them in an active and absorbable form to the desired absorption site using physiologically safe excipients. Therefore, one of the most important steps in the development of dosage forms for these drugs is to improve their solubility and/or dissolution rate. Chiou and Rigelman and Serajuddin *et al.* have used the solid dispersion (SD) technique for dissolution enhancement of poorly water-soluble drugs (4). Among the various approaches, the SD technique has often proved to be the most successful in improving the dissolution and bioavailability of poorly soluble active pharmaceutical ingredients because it is simple, economic, and advantageous. Sekiguchi and Obi were the first to propose the SD method using water-soluble carriers to improve the dissolution characteristics of poorly water-soluble drugs. Many water-soluble carriers have been employed for preparation of SD of poorly soluble drugs(5). The most common are polyethyleneglycols, polyvinyl pyrrolidone, mannitol and hydroxypropyl methylcellulose. Due to poor solubility in GI fluids, it results in low and erratic oral bioavailability(6). Glimepiride was selected as a model drug for dissolution enhancement studies in the present investigation. Attempts were made to enhance the dissolution of GMP using a SD technique. SDs of GMP with PVP K 30 was prepared in different ratios using solvent evaporation method and then tablets of best formulation of SD were formulated by using direct compression method (7). Tablet formulations were prepared by direct compression technique using super disintegrates povidone in different concentrations. SDs were evaluated for FTIR, XRD, SEM, *in vitro* dissolution profiles and developed tablet formulations were evaluated for various pharmaceutical characteristics viz. hardness, % friability, weight variation, drug content, disintegration time, *in vitro* dissolution profiles (8). Priyanka Shrestha, *et al.*, has studied that, Glimepiride is a poorly water-soluble oral hypoglycemic drug exhibiting poor dissolution pattern (9). The purpose of this work is to increase the dissolution rate of glimepiride by formation of solid dispersion with different water soluble carriers. Solid dispersion of glimepiride were prepared with polyvinyl pyrrolidone k-30, poloxamer 407, polyethylene glycol 6000 (PEG 6000), polyethylene glycol 4000 (PEG 4000), sodium starch glycolate, ludiflash and lactose at different weight ratios using the solvent evaporation and melting method(10). Physical

mixtures of the poloxamer 407 and povidone K-30 with glimepiride at different ratios were also used. In compare to physical mixtures with povidone K-30 and poloxamer 407, drug release from physical mixture PM (1/9) PVP K-30 was higher (65.93% within 5 min) than drug release from physical mixture with poloxamer 407 (56% within 5 min) the drug release from pure drug was 6.84% with in 5 minute(11). With the recent development in the screening of potential therapeutic agents, the number of poorly water soluble drugs have risen sharply and gained large interest due to the challenges in the oral solubility of the drug which leads to the major cause for which the techniques are meant to be implemented. One amongst such techniques is the formulation of solid dispersion for the solubility enhancement(12).

Materials and Methods:

Chemicals Used

Table 1: List of ingredients used in experiment

Name of the materials	Functional category	Sources of the chemicals
Glimepiride powder	Active pharmaceutical ingredient (API)	ESKAYEF BANGLADESH LTD, GAZIPUR.
Polyethylene glycol 4000(PEG 4000)	Carrier for solid dispersion	ALBION LABORATORIES LTD.
Polyethylene glycol 6000(PEG 6000)	Carrier for solid dispersion	ALBION LABORATORIES LTD.
PVP(Polyvinyl pyrrolidone)	Carrier for solid dispersion	LOCAL MAEKET
Eudragit	Carrier for solid dispersion	THE ACME LABORATORIES LTD.
Poloxomer 407	Carrier for solid dispersion	BASF
Potassium dihydrogen phosphate	Major salt of buffer solution	MERCK, MUMBAI.
Di-sodium hydrogen phosphate	Major salt of buffer solution	MERCK, MUMBAI.
Methanol	Aqueous Solvent	UNIVERSITY LABORATORY

Distilled water

Solvent for buffer solution, UNIVERSITY
used as washing agent too. LABORATORY

Fusion Method

Fusion method of solid dispersion of glimepiride is given below:

1. Desired amount out of drug and polymer were weighted out accurately e.g. PEG 4000
2. They were taken in a beaker
3. And placed it into water bath for melting at 70 °c.
4. After melting, accurately weighted amount of drug was added in that glass beaker containing PEG
5. Then they were mixed by glass rod to obtain a viscous mass.
6. The mixture was stirred vigorously for uniform mixing and was kept in normal room temperature for 72 hour until a solid mass was formed.
7. Solidified mixture was then grinded thoroughly with the help of mortar and pestle.
8. Then the powdered particle passed through a sieve (mesh size 40).
9. The resulted samples (Solid dispersion) were weighted and transferred in a fresh vial with proper labeling.
10. Finally, the SD formulation were kept in a desiccator until further investigation.

Table 2: Formulation of binary and ternary solid dispersion of glimepiride prepared by fusion method using different polymer at different ratio

Serial no	Carriers	Drug polymer ratio	Summarized form	Dispensing(mg)	Formulation coating	Method
1	PEG4000	1:1	Glim:PEG4000	300:300	G1	Fusion method
2	PEG4000	1:2	Glim:PEG4000	300:600	G2	Fusion method
3	PEG4000	1:3	Glim:PEG4000	300:900	G3	Fusion method
4	PEG4000	1:4	Glim:PEG4000	300:1200	G4	Fusion method
5	PEG4000	1:5	Glim:PEG4000	300:1500	G5	Fusion method
6	PEG6000	1:1	Glim:PEG6000	300:300	G6	Fusion method
7	PEG6000	1:2	Glim:PEG6000	300:600	G7	Fusion method
8	PEG6000	1:3	Glim:PEG6000	300:900	G8	Fusion method
9	PEG600	1:4	Glim:PEG6000	300:1200	G9	Fusion method
10	PEG6000	1:5	Glim:PEG6000	300:1500	G10	Fusion method

11	PEG4000:G LM:POVID ON	1:1:0.75	PEG4000:G11:PO VIDON	200:200:150	G11	Fusion method
12	PEG4000:G LM:POVID ON	1:1:0.50	PEG4000:G12:PO VIDON	200:200:100	G12	Fusion method
13	PEG4000:G LM:POVID ON	1:1:0.25	PEG4000:G13:PO VIDON	200:200:50	G13	Fusion method
14	PEG4000:G LM:POVID ON	1:1:0.00	PEG4000:G14:PO VIDON	200:200:00	G14	Fusion method
15	PEG6000:G LM:POVID ON	1:1:0.75	PEG6000:G15:PO VIDON	200:200:150	G15	Fusion method
66	PEG60000: GLM:POVI DON	1:1:0.50	PEG6000:G16:PO VIDON	200:200:100	G16	Fusion method
37	PEG600:G LM:POVID ON	1:1:0.25	PEG6000:G17:PO VIDON	200:200:50	G17	Fusion method
38	PEG600:G LM:POVID ON	1:1:0.00	PEG6000:G18:PO VIDON	200:200:00	G18	Fusion method

Preparation of 0.01 M phosphate buffer solution (pH=7.8)

0.58g of monobasic potassium phosphate and 8.86g of dibasic sodium phosphate anhydrous was dissolved in sufficient amount of distilled water. Then pH 7.8 was adjusted by adding 1N Sodium Hydroxide (NaOH) for the preparation of 1000ml buffer solution.

Preparation of Standard Curve of Glimepiride

1. 10mg of Glimepiride was accurately weighed and taken in 100ml volumetric flask.
2. Then phosphate buffer was added upto the mark to prepare primary stock solution.
3. Then 10 ml of this solution was taken in another 100ml volumetric flask and added buffer solution up to the mark. This solution was called stock solution.
4. Then serial dilution was carried out to get different drug concentration.
5. Then 1,2,3,4,5,6,7,8,9 and 10ml of stock solution was gradually taken to the test tube.

6. And 9,8,7,6,5,4,3,2,1 and 0 ml of buffer solution were added respectively to more 10 ml volume in each test tube.
7. These were then analyzed by UV spectrophotometer at 228 nm and the absorbance value were noted.
8. The absorbance value were plotted against drug concentrations.
9. Finally the standard curve of Glimepiride was produced.

***In-vitro* dissolution test for Glimepiride and solid dispersion formulation**

The *in vitro* dissolution studies for Glimepiride drug and SD formulation were performed using USP dissolution test apparatus type II (paddle type) method using 900 ml of phosphate buffer (pH 7.8) as dissolution medium. The temperature of the medium was maintained at $(37 \pm 0.5)^{\circ}\text{C}$ throughout the experiment. The samples contained glimepiride or its equivalent solid dispersion were placed in the dissolution medium. Paddle was used at a stirring rate of 75 rpm. A 5ml aliquot was withdrawn at predetermined time intervals of 5,15,30,45, and 60 min and then 5ml of fresh dissolution medium was replaced to maintain the constant volume of dissolution medium. The absorbance values of the collected samples was measured at 273nm using UV-visible spectrophotometer against dissolution medium as blank. The percent release of drug was calculated using the equation obtained from the standard curve in the media. ^[15].

Fourier transform Infra-red (FTIR) Spectroscopy

Infra-red studies was carried out to rule out interaction between drug and carrier used in formulation of solid dispersion by potassium bromide disc method using Infra-red spectrophotometer. FT-IR spectroscopy used to study the possibility of an interaction between drug and polymer in solid-state.

Fourier-transform infrared (FT-IR) spectra were obtained by using a Shimadzu IR 20 Spectrophotometer. The samples (Glimepiride or SDs) were previously grounded and mixed thoroughly with potassium bromide, an infrared transparent matrix, at 1:5 (Sample: KBr) ratio, respectively. The KBr discs were prepared by using corresponding machine. Scans were obtained at a resolution of 4 cm^{-1} , at wave numbers from 4000 to 500 cm^{-1} .

Results and Discussion

Glimepiride is an oral blood sugar-lowering drug in a class of medicine for controlling diabetes called Sulfonylurea. The aims of present investigation was to enhance the dissolution rate of poorly water soluble drugs glimepiride by preparing the solid dispersion using poloxomer 407, povidon, PEG 4000, PEG 6000. In this study solvent evaporation method and fusion/melting method was used for the preparation of solid dispersion of glimepiride.

Standard curve of glimepiride (Media: Phosphate buffer, pH 7.8)




Fig: 18 Standard curve of glimepiride

Dissolution profile of active Glimepiride

10 mg of pure Glimepiride was used for dissolution study. It was found that only 0.46% drug was released after 5 minutes and 15.83% was released within 60 minutes time interval. This showed that dissolution profile of glimepiride was very poorly.




Fig: 2Dissolution profile of glimepiride (API)

***In vitro* dissolution study of binary and ternary solid dispersion of glimepiride (fusion method)**

Comparative dissolution profile of active glimepiride and solid dispersion (SD) formulation (Glimepiride+PEG 4000) for their different ratio

Solid dispersion of glimepiride with PEG 4000 at different ratio G1 (1:1), G2 (1:2), G3 (1:3), G4 (1:4), G5 (1:5) and active glimepiride (API) were used for dissolution study. It was found that only 0.46% from active glimepiride, 21.46% from formulation G1, 56.30% from G2, 77.30% from G3, 64.15% from G4 and 76.84% from G5, were released after 5 min and 60.77% from G1, 83.66% from G2, 88.83% from G3, 65.47% from G4, 94.36% from G5, 15.29% from active glimepiride were released after 45min. Finally 72.88% from G1, 97.27% from G2, 90.91% from G3, 75.75% from G4, 99.76% from G5 were released within an hour time interval. Whereas only 15.83% was released from active glimepiride within an hour time interval.




Fig: 3. Average % release of drug from binary SD formulation containing PEG 4000 with different ratio

From the above data we can conclude that, the release pattern of drug from SD formulation containing PEG 4000 has increased gradually when the amount of PEG 4000 was increased. It was observed that solid dispersion formulation G5 showed substantially better result in 1:5 ratio in comparison to those of G1, G2, G3, and G4.

Comparative dissolution profile of active glimepiride and solid dispersion formulation (Glimepiride + PEG 6000) for their different ratio.

Solid dispersion of glimepiride with PEG 6000 at different ratio G6 (1:1), G7 (1:2), G8 (1:3), G9 (1:4), and G10 (1:5) were used for dissolution study. It was found that 24.46% from G6, 37.86% from G7, 25.84% from G8, 38.53% from G9, 53.76% from G10 were released after 5 min and 60.36% from G6, 68.30% from G7, 70.72% from G8, 50.28% from G9, and 64.82% from G10 were released after 45min. Finally 71.31% from G6, 88.99% from G7, 91.87% from G8, 51.01% from G9 and 49.71% from G10 were released within an hour time interval.




Fig: 4. Average % release of drug from SD formulation containing PEG 6000 with different ratio

From the above data it was found that, the release pattern from SD formulation containing PEG 6000 has increased gradually when the amount of PEG 6000 was decreased. It was observed that solid dispersion formulation G8 showed their better result in 1:3 ratios in comparison to those of G6, G7, G9, and G10.

Comparative dissolution profile of active glimepiride and solid dispersion (Glimepiride+ PEG 4000+ Povidon) for their different ratio

Ternary SD formulation of Glimepiride containing PEG 4000 and Povidon at different ratios of G11 (1:1:0.75), G12 (1:1:0.50), G13 (1:1:0.25), G14 (1:1:0) and API were used for dissolution study. It was found that 6% from G11, 1.38% from G12, 64.15% from G13, 21.46% from G14 and 0.46% from API were released after 5 min and 11.48% from G11, 14.19% from G12, 65.47% from G13, 60.77% from G14, 15.29% from API were released after 45 min. Finally 24.69% from G11, 19.35% from G12, 75.75% from G13, 72.88% from G14 and 15.83% from API were released in an hour time interval.




Fig: 5 Average % release of drug from ternary SD formulation containing PEG 4000 and Povidone.

From the above data we can conclude that the release pattern from the glimepiride containing two water soluble polymer PEG 4000 and Povidone have increased gradually when the amount of second polymer povidone were decreased in different ratio. It was observed SD formulation G13 (1:1:0.75) gave the best result in comparison to those of G11, G12, G14.

Comparative dissolution profile of pure glimepiride and solid dispersion formulation (Glimepiride+ PEG 6000+ Povidone) for their different ratio

Ternary SD formulation of Glimepiride containing PEG 6000 and Povidone at different ratio of G15 (1:1:0.75), G16 (1:1:0.50), G17 (1:1:0.25), G17 (1:1:0) and API were used in dissolution study. It was found that 63.46% from G15, 63.92% from G16, 23.90% from G17, 24.46% from G18 and 0.46% from API were released after 5 min and 73.71% from G15, 69.14% from G16, 61.84% from G17, 60.36% from G18, 15.29% from API were released after 45 min. Finally 75.50% from G15, 72.06% from G16, 69.09% from G17, 71.31% from G18 and 15.83% from API were released in an hour interval.




Fig: 6 Percent release from ternary SD formulations of glimepiride containing PEG 6000 and Povidone.

From the above data we can conclude that the release pattern from the glimepiride containing two water soluble polymer PEG 6000 and Povidone has increased gradually when the amount of second polymer povidone were increased in different ratio. It was observed SD formulation G15 (1:1:0.75) gave the best result in comparison to those of G16, G17, G18.

Release kinetics study of pure glimepiride and different solid dispersion formulations

We have chosen five SD formulation G5 (Glim + PEG 4000), G8 (Glim + PEG 6000), G13 (Glim+ PEG 4000 + Povidone), SE2 (Glim + Eudragit), SE9 (Glim + Poloxamer), which were

given most significant effect on the improvement of dissolution rate. These dissolution data were analyzed by zero order model, First order, Higuchi square root equation, Hixon crowell cube root law and Krosmeier Kinetics.

Zero order kinetics

Table 3 Comparative study of zero order kinetics of five solid dispersion formulations

Time	Percent release (%) G5	Percent release (%)G8	Percent release (%)G13
0	0	0	0
5	76.84615	25.84615	64.15385
15	80.73462	26.22051	61.04872
30	89.02692	50.36538	71.77051
45	94.36282	70.72051	65.47308
60	99.2641	91.87949	75.75385

First order release kinetics

Table 4: Comparative study of first order release kinetics of active glimepiride and five solid dispersion formulations

Time (min)	Log of % remaining drug(G5)	Log of % remaining drug (G8)	Log of % remaining drug(G13)	Log of % remaining drug(API)
0	2	2	2	2
5	1.364623	1.870134	1.554443	1.997991
15	1.284778	1.867936	1.590522	1.989849
30	1.040328	1.695785	1.450703	1.963352
45	0.751062	1.466564	1.538158	1.927929
60	-0.13318	0.909583	1.384643	1.92512

Higuchi release kinetics

Table 5: Comparative study of Higuchi release kinetics of active glimepiride and five solid dispersion formulations

Square root of time (SQRT)	%release of drug(G5)	%release of drug(G8)	% release of drug(G13)	% release of drug(API)	
0	0	0	0	0	
2.236068	76.84615	25.84615	64.15385	0.461538	
3.872983	80.73462	26.22051	61.04872	2.310256	
5.477226	89.02692	50.36538	71.77051	8.092308	
6.708204	94.36282	70.72051	65.47308	15.29103	Hixon crowell release kinetics
7.745967	99.2641	91.87949	75.75385	15.83718	

Table 6. Comparative study of Hixon crowell release kinetics of active glimepiride and five solid dispersion formulations

Time (min)	Cubic root of % remaining drug (G5)	Cubic root of % remaining drug(G8)	Cubic root of % remaining drug (G13)	Cubic root of % remaining drug (API)
0	4.641589	4.641589	4.641589	4.641589
5	2.850194	4.201244	3.297217	4.634437
15	2.680768	4.194162	3.389799	4.605566
30	2.222164	3.675036	3.044862	4.512847
45	1.779729	3.082155	3.256262	4.391806
60	0.90283	2.009992	2.894327	4.382347

Krosmeier release kinetics

Table 7: Comparative study of korsmeier release kinetics of active glimepiride and five solid dispersion formulations

Log time=T	Log fraction of drug release=log(% release/100)G5	Log fraction of drug release=log(% release/100)G8	Log fraction of drug release=log(% release/100)G13	Log fraction of drug release=log(% release/100)API
0.69897	-0.11438	-0.5876	-0.19278	-2.33579
1.176091	-0.09294	-0.58136	-0.21432	-1.63634
1.477121	-0.05048	-0.29787	-0.14405	-1.09193

1.653213	-0.0252	-0.15045	-0.18394	-0.81556
1.778151	-0.00321	-0.03678	-0.1206	-0.80032

Successive fractional dissolution time

Table 8: Table for Mean Dissolution Time (MDT) calculation

Formulation Code	T25%	T50%	T80%	MDT
Pure Drug	69.89354	110.7925	151.4168	105.5033
G5	0.000124	0.100156	9.39399	7.609336
G8	0.115755	0.427337	1.036083	0.546968
G13	7.09E-07	0.124536	448.1191	1186.845

Mean dissolution time (MDT) value was used to characterized the drug release rate form the dosage forms and the retarding efficiency of the polymer. Form the above Table 8, it was found that, a higher MDT value for the SD formulation G13 (glimepiride + PEG 4000 + Povidone) which was indicated that higher drug retarding ability of the polymer in the formulation.

Interpretation of Y equation ($Y = ax + b$) and correlation co efficient (R^2) value for different release kinetics of active glimepiride and SD formulation

Table: 9 Y equation and R^2 values of five SD formulations and active glimepiride

Formulation coding	Zero Order	1 st Order Kinetics	Higuchi model	Hixon Crowell model
	Y equation R ² Value	Y equation R ² Value	Y equation R ² Value	Y equation R ² Value
Pure drug	0.3007x-0.77 0.957	- 0.955	2.3177x+3.0603 0.861	- 0.956
G5	1.1172x+4.512 0.508	- 0.903	11.038x+25.468 0.751	- 0.822
G8	1.401x+7.9786 0.966	- 0.896	11.22x-4.5245 0.939	- 0.947
G13	0.7739x+22.763 0.419	- 0.525	7.8884x+22.13 0.66	- 0.487

The above data showed that R² value of active glimepiride, (R² = 0.957) and SD formulation G8 (R² = 0.966) were found substantially highest result in case of Zero order kinetics than other release kinetics. These R² value is near about 01, so it can be said that, active glimepiride, SD formulation G8 were followed zero order release pattern.

Another SD formulation G13 (R²= 0.66) was displayed best fitting with Higuchi release kinetics pattern. Because R²value of G13 was showed better value in case of Higuchi release kinetics.

Only one SD formulation G15 was best fitted with first order release pattern.

It was also observed that, in all case no formulation was fitted with Hixon Crowell kinetics model.


Glimepiride & polymer interaction study using FT-IR Spectroscopy:

Fourier Transform Infrared Spectroscopic (FTIR) study was concluded four samples-

1. Pure drug/API (Glimepiride)
2. Polymer (PEG 4000)
3. Polymer (Poloxamer 407)
4. Solid Dispersion (G3=Glimepiride+PEG4000, 1:3)
5. Solid Dispersion (G13=Glimepiride+Povidone+PEG 4000, 1:5)

FT-IR was used to characterize possible interactions between the drug and the carrier in solid Diclofenac Sodium.

FT-IR spectra of Pure Glimepiride



Tested by:
Name:

Checked by:
Name:

Approved by:
Name:

Reviewer's

SN.	Peak	Indication
01	1454.39 cm^{-1}	C-H bending
	1444.75 cm^{-1}	
	1437.03 cm^{-1}	

02	1659.82 cm ⁻¹	C=C Stretching
03	1595.20 cm ⁻¹	C=O Asymmetric Stretching
04	1345.41 cm ⁻¹	C-N Stretching
05	1317.44 cm ⁻¹	S=O Asymmetric Stretching
06	1150.59 cm ⁻¹	S=O Symmetric Stretching
07	1472.71 cm ⁻¹	NH ₂ bending

Reviewer's Copy




Fig: 4. FTIR of G3 (Glim+PEG4000)

Reviewer's

SN.	Peak	Indication
01	1150.59 cm^{-1}	C=O (stretch)
02	1360.84 cm^{-1} , 1465.96 cm^{-1} ,	C-H (bending)

	1472.71 cm ⁻¹ ,	
03	1671.39 cm ⁻¹	C=C (Stretch)
04	1671.39 cm ⁻¹ , 1696.47 cm ⁻¹ , 1706.11 cm ⁻¹ ,	C=O (Stretch), Carbonyl
05	1242.21 cm ⁻¹ , 1279.82 cm ⁻¹ ,	C-O (Stretch), Acid
06	1706.11 cm ⁻¹	Acyclic (Stretch), Ketone

From the above shown spectrum, we came to conclude that the spectrum seen in the pure glimepiride was also found in the case of solid dispersion with PEG4000. The spectrum were at same frequency range but some peaks were shifted to their near values. So we can say that there is no significant interaction between the drug & PEG4000, hence there was no chemical change in the PEG4000 when it was in solid dispersion form.

FTIR spectra of Glimepiride Solid dispersion with PEG4000 & Povidon prepared by Fusion method (G13= Glim+PEG4000+Povidon)




Fig: 5 FTIR of G13 (Glim+PEG4000+Povidone)

SN.	Peak	Indication
01	1060.89 cm ⁻¹ , 1079.22 cm ⁻¹ , 1150.59 cm ⁻¹ ,	C-O (Stretch)
02	1360.84 cm ⁻¹ , 1394.59 cm ⁻¹ ,	-C-H (bending)

	1437.03 cm ⁻¹ ,	
	1456.32 cm ⁻¹ ,	
	1465.00 cm ⁻¹ , &	
	14.72.71 cm ⁻¹ ,	
03	687.65 cm ⁻¹ ,	=C-H (Stretch)
	841.96 cm ⁻¹ ,	
	949.98 cm ⁻¹ ,	
	963.98 cm ⁻¹ , &	
	1000.13 cm ⁻¹	
04	1437.03 cm ⁻¹ ,	C=C (Stretch)
	1456.32 cm ⁻¹ ,	
	1465.00 cm ⁻¹ ,	
	14.72.71 cm ⁻¹ ,&	
	1595.20 cm ⁻¹	

From the above shown spectrum, we came to conclude that the spectrum seen in the pure glimepiride was also found in the case of solid dispersion with PEG4000 & Povidone. The spectrum were at same frequency range but some peaks were shifted to their near values. So we can say that there is no significant interaction between the drugs, PEG4000, & Povidone, hence there was no chemical change in the PEG4000, and Povidone, when it was in solid dispersion form.

Conclusion

Solid dispersion has attracted considerable interest as an efficient means of improving the dissolution rate and bioavailability of hydrophobic drugs. In the present study, solid dispersions

of Glimepiride with different hydrophilic carriers in different ratios were prepared by physical mixing and fusion method to improve water solubility and dissolution characteristics. The preparation of solid dispersion of Glimepiride by fusion method has been proven to be successful. This research showed that when Glimepiride was dispersed in suitable water-soluble carriers such as PEG 6000, PEG 4000 and Eudragit E-100, Poloxamer 407 and Povidone. Its dissolution were enhanced compared with pure drug. Fusion method of the poloxamer 407 and Eudragit with glimepiride at different ratios were also used. It was found the drug was released 0.46% after 5 minutes and only 15.83% within 60 minutes from active glimepiride on the other hand the release pattern of glimepiride from the binary formulation containing PEG 4000 in 1:5 (Formulation coding: G5) showed the best result. It was found that the ternary different SD formulation containing (PEG4000: Glimepiride:Povidon) in ratio 1:1:0.25 (Formulation coding were : G13) showed the best result. It was also studied that the release kinetics of glimepiride of different SD formulation with different ratio such as, First order release kinetics, Higuchi, Krosmeier, Hixon crowell plot, and also be noted the MDT calculation for improving the solubility of glimepiride.. *In-vitro* dissolution data also proves that percent release of drug from binary SDs was not similar with ternary SDs. Ternary SDs is more effective to increase the diclofenac sodium release rate. The water soluble carrier may operate in the micro environment (diffusion layer) immediately surrounding the drug particles in the early stage of dissolution, since the carrier completely dissolves in short time thus enhancing the solubility & dissolution of drug.

REFERENCES

1. Dahlberg C, Millqvist-Fureby A, Schulte M. Surface comparison and contact angle relationship for differently prepared solid dispersion. *European Journal of Pharmacy and biopharmacy*, 2008; 70(2): 478-485.
2. Singh S, Baghel RS, Yadav L. A review on solid dispersion. *International Journal of Pharmacy and Life Sciences*, 2011; 2(9): 1078-1095.
3. Costantino HR, Firouzabadian L, Wu C, Carrasquillo KG, Griebenow K, Zale SE et al. Protein spray freeze drying. Effect of formulation variables on particle size and stability. *Journal of Pharmaceutical Science*, 2002;91(2): 388-395.
4. Arunachalam A, Karthikeyan M, Konam K, Prasad PH, Sethuraman S, Ashutoshkumar A. A review on solid dispersion. *Current Pharmaceutical Research*, 2010; 1(82): 82-90.
5. Deepti, Dureja H, Madan AK. Solid dispersion adsorbates for enhancement of dissolution rates of drugs. *PDA Journal of Pharmaceutical Science and Technology*, 2007; 61(2): 97-101.
6. Bandarkar FS, Khattab IS. Lyophilized Gliclazide poloxamer solid dispersions for enhancement of in vitro dissolution and in vivo bioavailability. *International Journal of Pharmacy and Pharmaceutical Sciences*, 2011; 3: 122-127.

7. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. *Journal of Pharmaceutical Sciences*, 1971; 60: 1281–1302.
8. Nasir ASM, Aarti MJ, Manoj M, Bari, Randhir B, Chavhan, Barhate SD. New dimensions to Solid Dispersion. *Indo American Journal of Pharmaceutical Research*, 2013; 3(4): 3247.
9. Chiou WL, Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. *Journal of Pharmaceutical Sciences*, 1969; 58: 1505–1510.
10. Sonpal RN, Lalwani AN, Darji VC, Patel KR. Solid dispersion; an efficient tool for increasing bioavailability of poorly soluble drugs. *International Journal of Pharmaceutical Sciences Review and Research*, 2011; 8(1): 44-45.
11. Costantino HR, Firouzabadian L, Wu C, Carrasquillo KG, Griebenow K, Zale SE et al. Protein spray freeze drying. Effect of formulation variables on particle size and stability. *Journal of Pharmaceutical Science*, 2002; 91(2): 388-395.
12. Dahlberg C, Millqvist-Fureby A, Schuleit M. Surface comparison and contact angle relationship for differently prepared solid dispersion. *European Journal of Pharmacy and biopharmacy*, 2008; 70(2): 478-485.
13. Rani KS, Poornima G, Krishnaveni A, Brahmaiah B, Nama S. A review on solid dispersions. *Asian Journal of Pharmaceutical Research*, 2013; 3(2): 93-98.
14. Nagarajan K, Rao MG. Formulation and Dissolution Studies of Solid Dispersions of Nifedipine. *Indian Journal of Novel Drug Delivery*, 2010; 2: 96-98.
15. Kalpana P, Manish S, Sharma K, Dinesh, Jain K, Surendra. Solid dispersion: Approaches, technology involved unmet need and Challenges. *Drug Invention Today*, 2010; 2(7): 349-357.